Otsuka, Lundbeck Seek Alzheimer's Agitation Claim For Antipsychotic

Otsuka and Lundbeck are seeking to expand the use of psychiatry drug Rexulti into Alzheimer's agitation to up the product's commercial prospects, but mixed Phase III data for the drug mean a third regulatory nod is uncertain.